Apollo Micro Systems Regulatory Approval

Apollo Micro Systems Earnings Call Transcript: Key Takeaways

Apollo reported record-breaking performance driven by defense indigenization, yet consolidated margins are temporarily dampened by the transition of loss-making subsidiary Ideal Explosives.

Call

Guides 45% growth

Apollo Micro Systems Business Update

Apollo Micro Systems' MD issued a shareholder letter on Q2 FY27 performance and missile-technology expansion. It cites a new ShauryAstra subsidiary for complete weapon systems.

Apollo Micro Systems Results Update

Apollo Micro Systems reported record Q2 FY27 standalone revenue of ₹306 Crore, up 97% quarter-on-quarter. H1 FY27 consolidated revenue rose 78% year-on-year to ₹639 Crore.

Apollo Micro Systems Investor Presentation: Key Takeaways

Apollo Micro Systems Q2 FY27 consolidated revenue ₹3,881.5 Mn (+72.3% YoY), EBITDA ₹1,111.8 Mn (+87.8%), PAT ₹461.5 Mn (+53.7%); H1 revenue ₹6,394.4 Mn (+78.2%). Strategy: Vision 2036 global OEM, explosives integration.

Apollo Micro Systems Q2 FY27 Results: Net Profit ₹46.2 Cr, Up 54.0% YoY

Apollo Micro Systems Ltd reported revenue from operations of ₹388.1 Cr (+72.3% YoY) and net profit of ₹46.2 Cr (+54.0% YoY) for Q2 FY27.

Key figure

Net profit ₹46.2 Cr · +54.0% YoY

Apollo Micro Systems Production Started

Group company IDL Explosives has commissioned its 9,000 MT Bolkunda Silo plant near Asansol. The facility expands IDL's bulk explosives delivery network in India's coal belts.

bulk explosives silo capacity

9000 MT

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.